AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37004106 — intervention group
Group type: EXPERIMENTAL
Intervention: NE intervention (prevent STIs, HIV, HCV, and teen pregnancy)
Number of subjects: 456
Study 37004111 — intervention group
Group type: EXPERIMENTAL
Intervention: AGRF biofeedback
Number of subjects: 9
Study 37004111 — intervention group
Group type: EXPERIMENTAL
Intervention: TLA biofeedback
Number of subjects: 9
Study 37004111 — intervention group
Group type: COMPARATOR
Intervention: No biofeedback
Number of subjects: 9
Study 37004206 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 37004206 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 37004331 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 71
Study 37004331 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotics (OAP)
Number of subjects: 71
Study 37004342 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial treatment (n = 18)
Number of subjects: 36
Study 37004342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study 37004380 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching 125% of arm's length
Number of subjects: 23
Study 37004380 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum reaching task
Number of subjects: 23
Study 37004380 — intervention group
Group type: COMPARATOR
Intervention: Arm's length reaching task
Number of subjects: 23
Study 37004392 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loading bilaterally with 4 kg
Number of subjects: 21
Study 37004392 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loading bilaterally above 6 kg
Number of subjects: 21
Study 37004392 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loading on the lumbar area at 6 kg
Number of subjects: 21
Study 37004392 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loading on the lumbar area at 4 kg
Number of subjects: 21
Study 37004392 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral weight placement above 4 kg
Number of subjects: 21
Study 37004392 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral weight placement above 6 kg
Number of subjects: 21
Study 37004526 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning model
Number of subjects: 311
Study 37004526 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive CAD
Number of subjects: 311
Study 37004526 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obstructive CAD
Number of subjects: 311
Study 37004599 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib (240 mg once-daily)
Number of subjects: 53
Study 37004599 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib (80 mg once-daily)
Number of subjects: 53
Study 37004599 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib (160 mg once-daily)
Number of subjects: 53
Study 37004599 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Number of subjects: 53
Study 37004656 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 SC monotherapy (120 or 240 mg every 2 weeks)
Number of subjects: 66
Study 37004656 — intervention group
Group type: COMPARATOR
Intervention: CT-P13 SC combotherapy (with immunosuppressants)
Number of subjects: 66
Study 37004656 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 SC monotherapy
Number of subjects: 66
Study 37004656 — intervention group
Group type: COMPARATOR
Intervention: CT-P13 SC combotherapy
Number of subjects: 66
Study 37004656 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 SC monotherapy (in ADA-positive patients)
Number of subjects: 66
Study 37004656 — intervention group
Group type: COMPARATOR
Intervention: CT-P13 SC combotherapy (in ADA-positive patients)
Number of subjects: 66
Study 37004692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandala and technology-based breastfeeding program (including Zoom and WhatsApp platforms) with three education modules via WhatsApp
Number of subjects: 66
Study 37004692 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 66
Study 37004712 — intervention group
Group type: EXPERIMENTAL
Intervention: lerapolturev (5 × 10) administered as a single dose intracerebrally by convection enhanced delivery
Number of subjects: 12
Study 37004712 — intervention group
Group type: EXPERIMENTAL
Intervention: lerapolturev
Number of subjects: 12
Study 37004712 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose bevacizumab
Number of subjects: 12
Study 37004875 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of adaptation to threonine intake
Number of subjects: 11
Study 37004875 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of adaptation to threonine intake
Number of subjects: 11
Study 37004875 — intervention group
Group type: COMPARATOR
Intervention: 1 day of adaptation to threonine intake
Number of subjects: 11
Study 37004887 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (combination therapy)
Number of subjects: 297
Study 37004887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (monotherapy)
Number of subjects: 297
Study 37004944 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 273
Study 37004944 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 273
Study 37004944 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI-related CS
Number of subjects: 273
Study 37004944 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-AMI-related CS
Number of subjects: 273
Study 37005448 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 239
Study 37005486 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-Predict intervention with risk feedback letters
Number of subjects: 2472
Study 37005486 — intervention group
Group type: COMPARATOR
Intervention: Usual screening (control)
Number of subjects: 2472
Study 37005580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.3 mg/kg bolus over 10 min, followed by 0.3 mg/kg/h infusion)
Number of subjects: 90
Study 37005580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 mcg/kg bolus over 10 min, followed by 0.5 mg/kg/h infusion)
Number of subjects: 90
Study 37005580 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 90
Study 37005596 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking exercise using lower body positive pressure treadmill
Number of subjects: 26
Study 37005596 — intervention group
Group type: COMPARATOR
Intervention: Forward walking exercise using lower body positive pressure treadmill
Number of subjects: 26
Study 37005636 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict rate control
Number of subjects: 350
Study 37005636 — intervention group
Group type: COMPARATOR
Intervention: Lenient rate control
Number of subjects: 350
Study 37005647 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS-active stimulus (10 Hz rTMS over individualized-targeted selection area)
Number of subjects: 30
Study 37005647 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulus
Number of subjects: 30
Study 37005647 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS-active stimulus (10 Hz rTMS)
Number of subjects: 30
Study 37005655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-luteal phase target quit date
Number of subjects: 1200
Study 37005655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-follicular phase target quit date
Number of subjects: 1200
Study 37005655 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (15-30 days after enrollment)
Number of subjects: 1200
Study 37005891 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Number of subjects: 16
Study 37005891 — intervention group
Group type: COMPARATOR
Intervention: CINRG DNHS (historical control)
Number of subjects: 16
Study 37005961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 129
Study 37005959 — intervention group
Group type: EXPERIMENTAL
Intervention: CONUT score
Number of subjects: 371
Study 37005959 — intervention group
Group type: COMPARATOR
Intervention: None (mild malnutrition risk group)
Number of subjects: 371
Study 37005959 — intervention group
Group type: COMPARATOR
Intervention: Moderate and severe malnutrition risk group
Number of subjects: 371
Study 37005959 — intervention group
Group type: EXPERIMENTAL
Intervention: Other nutritional indices (GNRI, PNI)
Number of subjects: 371
Study 37005963 — intervention group
Group type: EXPERIMENTAL
Intervention: Forehead (FH) sweat analyte concentrations
Number of subjects: 8
Study 37005963 — intervention group
Group type: EXPERIMENTAL
Intervention: Right scapula (RS) sweat analyte concentrations
Number of subjects: 8
Study 37005963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol concentration over time
Number of subjects: 8
Study 37005963 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF concentration over time
Number of subjects: 8
Study 37005963 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra concentration over time
Number of subjects: 8
Study 37005963 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 concentration over time
Number of subjects: 8
Study 37005966 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 140
Study 37005966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 37006132 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis group
Number of subjects: 71
Study 37006132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivitis group
Number of subjects: 71
Study 37006132 — intervention group
Group type: EXPERIMENTAL
Intervention: GCF PLAP-1, sclerostin and TNF-α levels
Number of subjects: 71
Study 37006227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 184
Study 37006227 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 184
Study 37006503 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive trans-sulcal parafascicular surgery (MIPS) approach for ICH removal using the BrainPath
Number of subjects: 0
Study 37006503 — intervention group
Group type: COMPARATOR
Intervention: Standard of care involving intensive supportive therapy
Number of subjects: 0
Study 37006506 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intraprocedural angioplasty and/or stenting (EAS)
Number of subjects: 475
Study 37006506 — intervention group
Group type: COMPARATOR
Intervention: Non-angioplasty and/or stenting (NAS)
Number of subjects: 475
Study 37006506 — intervention group
Group type: COMPARATOR
Intervention: Late intraprocedural angioplasty and/or stenting (LAS)
Number of subjects: 475
Study 37006506 — intervention group
Group type: EXPERIMENTAL
Intervention: EAS, NAS, LAS
Number of subjects: 475
Study 37007063 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SABRT) at a starting dose of 40 Gy in 5 fractions
Number of subjects: 10
Study 37007572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic normoglycemic clamp (HNC) during surgery (insulin 2 mU/kg/min followed by 20% dextrose infusion to maintain blood glucose between 4.0 and 6.0 mmol/L until end of surgery)
Number of subjects: 66
Study 37007572 — intervention group
Group type: COMPARATOR
Intervention: Standard metabolic care (control group)
Number of subjects: 66
Study 37007675 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) models
Number of subjects: 1
Study 37007675 — intervention group
Group type: COMPARATOR
Intervention: Multilinear model
Number of subjects: 1
Study 37007675 — intervention group
Group type: EXPERIMENTAL
Intervention: Small datasets recorded later in the experiment
Number of subjects: 1
Study 37007686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-related household job losses
Number of subjects: 0
Study 37007686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-related economic hardship
Number of subjects: 0
Study 37007686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-related economic hardship and psychosocial distress
Number of subjects: 0
Study 37007686 — intervention group
Group type: COMPARATOR
Intervention: Pandemic-related psychosocial distress
Number of subjects: 0
Study 37007686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepandemic social resources
Number of subjects: 0
Study 37007736 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal nerve block
Number of subjects: 192
Study 37007741 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype-tailored lifestyle intervention (PLI) with various approaches based on phenotype: time-restricted volumetric low-calorie diet, low-calorie diet with pre-meal protein supplementation, low-calorie diet with intensive behavioral therapy, low-calorie diet with post-workout protein supplementation and high-intensity interval training.
Number of subjects: 165
Study 37007741 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle intervention (SLI) with low-calorie diet, moderate physical activity, and weekly behavioral therapy sessions.
Number of subjects: 165
Study 37007741 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PLI vs SLI
Number of subjects: 165
Study 37007743 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Tα1) therapy
Number of subjects: 502
Study 37007743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 37007788 — intervention group
Group type: EXPERIMENTAL
Intervention: FNC (AZVUDINE) added to standard treatment
Number of subjects: 281
Study 37007788 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to standard treatment
Number of subjects: 281
Study 37007930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks or 2 mg every 8 weeks after 5 initial monthly doses
Number of subjects: 710
Study 37007930 — intervention group
Group type: COMPARATOR
Intervention: Macular laser treatment (control)
Number of subjects: 710
Study 37007930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 710
Study 37008165 — intervention group
Group type: EXPERIMENTAL
Intervention: CTPS1 small molecule inhibitor
Number of subjects: 0
Study 37008185 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal group healthy relationship education (MotherWise)
Number of subjects: 507
Study 37008185 — intervention group
Group type: COMPARATOR
Intervention: No additional services (Control)
Number of subjects: 507
Study 37008718 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood tacrolimus trough concentration
Number of subjects: 689
Study 37008796 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical monitoring using interactive web application (R-Shiny)
Number of subjects: 422
Study 37008796 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical monitoring
Number of subjects: 422
Study 37008796 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive statistical monitoring
Number of subjects: 422
Study 37008880 — intervention group
Group type: EXPERIMENTAL
Intervention: RCMP cadets
Number of subjects: 0
Study 37008891 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin cup and bonded maxillary bite block treatment
Number of subjects: 0
Study 37008891 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37008942 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and gonadotropin-releasing hormone analogue (GnRHa) for four years
Number of subjects: 16
Study 37008942 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 16
Study 37009114 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline titrated to 1 mg bid, brief behavioral counseling, and TIQ texting support
Number of subjects: 300
Study 37009114 — intervention group
Group type: COMPARATOR
Intervention: Placebo, brief behavioral counseling, and TIQ texting support
Number of subjects: 300
Study 37009114 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (advice to quit and TIQ)
Number of subjects: 300
Study 37009114 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline titrated to 1 mg bid
Number of subjects: 300
Study 37009236 — intervention group
Group type: EXPERIMENTAL
Intervention: New legislation banning tobacco sales in supermarkets
Number of subjects: 0
Study 37009236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco industry strategies
Number of subjects: 0
Study 37009425 — intervention group
Group type: EXPERIMENTAL
Intervention: Guajava leaf treatment, specific dosage and duration not mentioned
Number of subjects: 0
Study 37009425 — intervention group
Group type: COMPARATOR
Intervention: Various treatments for COVID-19, including antiviral agents
Number of subjects: 0
Study 37009678 — intervention group
Group type: EXPERIMENTAL
Intervention: ETBR-mediated dilation in women with T1D
Number of subjects: 19
Study 37009678 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle oxidative capacity in women with T1D
Number of subjects: 19
Study 37009678 — intervention group
Group type: COMPARATOR
Intervention: ETBR-mediated dilation
Number of subjects: 19
Study 37009731 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy
Number of subjects: 104
Study 37009915 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home serological tests detecting antibodies against SARS-CoV-2 (nucleocapsid or spike antigen), conducted from 1 May 2021 to 31 October 2021.
Number of subjects: 1058
Study 37009915 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated children aged 12-17 years.
Number of subjects: 1058
Study 37009976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab plus standard of care (SoC)
Number of subjects: 0
Study 37009976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab plus SoC
Number of subjects: 0
Study 37009976 — intervention group
Group type: COMPARATOR
Intervention: SoC alone
Number of subjects: 0
Study 37010012 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-371797
Number of subjects: 8
Study 37010101 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced LVEF (LVEF <50%)
Number of subjects: 348
Study 37010101 — intervention group
Group type: COMPARATOR
Intervention: Preserved LVEF (LVEF ≥50%)
Number of subjects: 348
Study 37010101 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurohormonal antagonist therapy
Number of subjects: 348
Study 37010101 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 348
Study 37010101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adverse events
Number of subjects: 348
Study 37010145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 810
Study 37010196 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy (conventional techniques)
Number of subjects: 1679
Study 37010196 — intervention group
Group type: COMPARATOR
Intervention: Instrumental techniques
Number of subjects: 1679
Study 37010196 — intervention group
Group type: COMPARATOR
Intervention: Forced passive expiratory techniques
Number of subjects: 1679
Study 37010196 — intervention group
Group type: COMPARATOR
Intervention: Slow expiratory techniques
Number of subjects: 1679
Study 37010196 — intervention group
Group type: COMPARATOR
Intervention: Forced expiratory techniques
Number of subjects: 1679
Study 37010251 — intervention group
Group type: EXPERIMENTAL
Intervention: LY01005
Number of subjects: 290
Study 37010251 — intervention group
Group type: COMPARATOR
Intervention: Goserelin implant
Number of subjects: 290
Study 37010267 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based eye test for self-assessing visual function
Number of subjects: 22
Study 37010495 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SAE positive DM
Number of subjects: 49
Study 37010549 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg qd + Sorafenib 200 mg bid 5 days-on/2 days-off
Number of subjects: 43
Study 37010549 — intervention group
Group type: COMPARATOR
Intervention: Everolimus 5 mg qd + Sorafenib (standard schedule)
Number of subjects: 43
Study 37010829 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 273
Study 37010829 — intervention group
Group type: COMPARATOR
Intervention: Procedural Sedation
Number of subjects: 273
Study 37010871 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer family mealtime duration (50% longer, average 10 minutes longer)
Number of subjects: 50
Study 37010871 — intervention group
Group type: COMPARATOR
Intervention: Regular family mealtime duration (control)
Number of subjects: 50
Study 37010871 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer family mealtime duration
Number of subjects: 50
Study 37010888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program with digital support, 9 sessions
Number of subjects: 5
Study 37010901 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF medications (intravitreal bevacizumab, aflibercept, ranibizumab)
Number of subjects: 353
Study 37010901 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF medications
Number of subjects: 353
Study 37010911 — intervention group
Group type: EXPERIMENTAL
Intervention: Warna-Warni Waktu (intervention group, n=924)
Number of subjects: 2000
Study 37010911 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (control group, n=923)
Number of subjects: 2000
Study 37010918 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 10
Study 37010918 — intervention group
Group type: COMPARATOR
Intervention: Dichoptic action video gaming
Number of subjects: 10
Study 37010923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripartite panel of biologically connected immune and metabolic markers
Number of subjects: 1445
Study 37010923 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and stool samples from infants with suspected sepsis
Number of subjects: 1445
Study 37010923 — intervention group
Group type: COMPARATOR
Intervention: Blood and stool samples from control infants
Number of subjects: 1445
Study 37010988 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (nal-IRI) administered on days 1 and 15, and veliparib on days 5-12 and 19-25 in 28-day cycles.
Number of subjects: 18
Study 37010988 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable as this is a phase I study without a control group.
Number of subjects: 18
Study 37011013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 34